Treatment advances in antiphospholipid syndrome: 2022 update

Curr Opin Pharmacol. 2022 Aug:65:102212. doi: 10.1016/j.coph.2022.102212. Epub 2022 May 27.


Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or non-thrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional treatment strategies of antiphospholipid syndrome focuses on antithrombotic agents, however they are usually not effective for microvascular and non-thrombotic manifestations of aPL. In parallel to our increased understanding of the mechanisms of aPL-mediated clinical events, immunosuppression has been increasingly used in aPL-positive patients. This review focuses on the role of potential targeted immunosuppressive treatments in APS (B-cell inhibition, complement inhibition, mechanistic target of rapamycin inhibition, and traditional rheumatologic disease-modifying agents including hydroxychloroquine) and future perspectives.

Publication types

  • Review

MeSH terms

  • Antibodies, Antiphospholipid / therapeutic use
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome* / drug therapy
  • Female
  • Humans
  • Immunosuppression Therapy
  • Pregnancy
  • Thrombosis* / drug therapy


  • Antibodies, Antiphospholipid
  • Anticoagulants